



NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

NC MEDICAID DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Thursday, October 8, 2026, 1:00 p.m.– 5:00 p.m.
Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. **The categories below contain recommendations that will require a vote by the PDL Panel.**

Analgesics

1. Neuropathic Pain
2. Opioid Analgesics - Short Acting Schedule II Opioids
3. NSAIDS

Anticonvulsants

1. Second Generation

Anti-Infectives – Systemic

1. Anti-Infectives – Tetracycline Derivatives
2. Antivirals - Hepatitis B Agents and Related
3. Antifungals

Behavioral Health

1. Antidepressants (Other)
2. Atypical Antipsychotics (Oral/Transdermal)
3. Antihyperkinesis/ADHD

Cardiovascular

1. Angiotensin II Receptor Blockers
2. Angiotensin II Receptor Blocker Diuretic Combinations
3. Endothelin Receptor Antagonists
4. Sympatholytics And Combinations

Endocrinology

1. Hypoglycemics: Long-Acting Insulin
2. DPP-IV Inhibitors and Combinations
3. SGLT-2 Inhibitors and Combinations

Gastrointestinal

1. Antiemetic-antivertigo Agents

Hematologic

1. Colony Stimulating Factors

Osteoporosis

1. Bone Resorption Suppression and Related Agents

Respiratory

1. Inhaled Anticholinergics / COPD Agents

Topicals

1. Rosacea Agents
2. Steroids (Low Potency)

Miscellaneous

1. Glucocorticoid Steroids (Oral)
2. Cytokine And CAM Antagonists
3. Immunosuppressants
4. Disposable insulin Delivery Devices

Labeler Termination and Obsolete Drugs

1. Labeler Termination: Drugs that are no longer participating in the MDRP
2. Obsolete Drugs: Drugs that are no longer manufactured

- V. Closing comments and adjournment